Quinazoline analogs as receptor tyrosine kinase inhibitors

Patent metadata

Field	Value
Publication number	US-2017260202-A1
Application number	US-201715606928-A
Country	US
Kind code	A1
Filing date	May 26, 2017
Priority date	Aug 14, 2003
Publication date	Sep 14, 2017
Grant date	—

Abstract

This invention provides compounds of Formula 11:

First claim

What is claimed is:

1 . A compound of Formula 11, wherein:

R 1 is a substituted or unsubstituted, monocyclic or bicyclic, aryl or heteroaryl moiety;
R 2 is H or a substituted or unsubstituted C 1-8 alkyl, allyl, and substituted benzyl;
R 3 is hydrogen;
R 6 is hydrogen;
each X is independently R 8 or R 9 ;
R 8 and R 9 are independently selected from the group consisting of hydrogen, trifluoromethyl, C 1 -C 10 alkyl, (CH 2 ) 0-4 C 3 -C 10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, partially unsaturated heterocyclyl and heterocyclylalkyl, wherein said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, partially unsaturated heterocyclyl, and heterocyclylalkyl is optionally substituted with one to five groups independently selected from the group consisting of oxo, halogen, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 10 cycloalkyl, C 3 -C 10 cycloalkylalkyl, cyano, nitro, OR 6 , NR 6 R 8 , SR 6 , trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, partially unsaturated heterocyclyl and heterocyclylalkyl;
or R 8 and R 9 together with the atoms to which they are attached may be independently joined to complete a 3 to 10 membered cycloalkyl ring or heterocycloalkyl ring optionally containing one or more additional heteroatoms selected from the group consisting of O, S, SO, SO 2 and NR 6 , wherein each ring carbon may be optionally substituted with one to three groups independently selected from the group consisting of halogen, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 10 cycloalkyl, C 3 -C 10 cycloalkylalkyl, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, OR 8 , NR 6 R 8 , SR 6 , heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, partially unsaturated heterocyclyl and heterocyclylalkyl, provided said ring does not contain two adjacent O or two adjacent S atoms.

2 . A compound of claim 1 , wherein R 2 is hydrogen.

3 . A compound of claim 1 , wherein each R 8 and R 9 are independently selected from hydrogen and C 1 -C 10 alkyl.

4 . A compound of claim 3 , wherein each R 8 and R 9 are independently selected from hydrogen and methyl.

5 . A compound of claim 1 , wherein the compound of Formula 11 is selected from the group consisting of:

Assignees

• Array Biopharma Inc

Inventors

• Wallace Eli
• Topalov George
• Lyssikatos Joseph
• Buckmelter Alexandre
• Zhao Qian

Classifications

• C07D401/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D413/12

  linked by a chain containing hetero atoms as chain links · CPC title

• A61P35/04

  specific for metastasis · CPC title

• C07D498/10 Primary

  Spiro-condensed systems · CPC title

• C04B35/632

  Organic additives · CPC title